These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 27745828

  • 21. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis.
    Chen M, Liu Y, Jin J, He Q.
    Ren Fail; 2016; 38(4):581-7. PubMed ID: 26915531
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials.
    Yang W, Cai X, Zhang S, Han X, Ji L.
    Diabetes Metab Res Rev; 2021 Mar; 37(3):e3391. PubMed ID: 32741073
    [Abstract] [Full Text] [Related]

  • 29. Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials.
    Abbas AS, Dehbi HM, Ray KK.
    Diabetes Obes Metab; 2016 Mar; 18(3):295-9. PubMed ID: 26510994
    [Abstract] [Full Text] [Related]

  • 30. The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes.
    Stoian AP, Sachinidis A, Stoica RA, Nikolic D, Patti AM, Rizvi AA.
    Metabolism; 2020 Aug; 109():154295. PubMed ID: 32553739
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus patients with moderate to severe renal impairment: a meta-analysis.
    Chen Y, Men K, Li XF, Li J, Liu M, Fan ZQ.
    Eur Rev Med Pharmacol Sci; 2018 Jun; 22(11):3502-3514. PubMed ID: 29917205
    [Abstract] [Full Text] [Related]

  • 32. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.
    Li L, Li S, Deng K, Liu J, Vandvik PO, Zhao P, Zhang L, Shen J, Bala MM, Sohani ZN, Wong E, Busse JW, Ebrahim S, Malaga G, Rios LP, Wang Y, Chen Q, Guyatt GH, Sun X.
    BMJ; 2016 Feb 17; 352():i610. PubMed ID: 26888822
    [Abstract] [Full Text] [Related]

  • 33. Pancreatic Safety of Sitagliptin in the TECOS Study.
    Buse JB, Bethel MA, Green JB, Stevens SR, Lokhnygina Y, Aschner P, Grado CR, Tankova T, Wainstein J, Josse R, Lachin JM, Engel SS, Patel K, Peterson ED, Holman RR, TECOS Study Group.
    Diabetes Care; 2017 Feb 17; 40(2):164-170. PubMed ID: 27630212
    [Abstract] [Full Text] [Related]

  • 34. Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis.
    Liu D, Jin B, Chen W, Yun P.
    BMC Pharmacol Toxicol; 2019 Mar 04; 20(1):15. PubMed ID: 30832701
    [Abstract] [Full Text] [Related]

  • 35. Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials.
    Kongwatcharapong J, Dilokthornsakul P, Nathisuwan S, Phrommintikul A, Chaiyakunapruk N.
    Int J Cardiol; 2016 May 15; 211():88-95. PubMed ID: 26991555
    [Abstract] [Full Text] [Related]

  • 36. Heart Failure Hospitalization with DPP-4 Inhibitors: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Singh AK, Singh R.
    Indian J Endocrinol Metab; 2019 May 15; 23(1):128-133. PubMed ID: 31016167
    [Abstract] [Full Text] [Related]

  • 37. Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors.
    Fiorentino TV, Sesti G.
    Endocrine; 2016 Aug 15; 53(2):373-80. PubMed ID: 26611248
    [Abstract] [Full Text] [Related]

  • 38. Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors.
    Scirica BM, Im K, Murphy SA, Kuder JF, Rodriguez DA, Lopes RD, Green JB, Ruff CT, Sabatine MS.
    Clin Cardiol; 2022 Jul 15; 45(7):794-801. PubMed ID: 35715946
    [Abstract] [Full Text] [Related]

  • 39. Safety of dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
    Doni K, Bühn S, Weise A, Mann NK, Hess S, Sönnichsen A, Pieper D, Thürmann P, Mathes T.
    Ther Adv Drug Saf; 2022 Jul 15; 13():20420986211072383. PubMed ID: 35111291
    [Abstract] [Full Text] [Related]

  • 40. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E, Cigolini M.
    Nutr Metab Cardiovasc Dis; 2016 Apr 15; 26(4):273-84. PubMed ID: 27038847
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.